Suppliers and packagers for REZUROCK

REZUROCK

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Kadmon Pharms Llc	REZUROCK	belumosudil mesylate	TABLET;ORAL	214783	NDA	Kadmon Pharmaceuticals, LLC	79802-200-30	1 BOTTLE in 1 CARTON (79802-200-30) / 30 TABLET in 1 BOTTLE	2021-07-16

REZUROCK API Manufacturing Landscape

Last updated: February 19, 2026

This analysis details the supply chain for REZUROCK (lifileucel), a cell therapy for metastatic melanoma. The manufacturing process is complex, relying on specialized facilities and raw materials. Key suppliers are identified, and potential supply chain vulnerabilities are assessed.

What is REZUROCK?

REZUROCK, also known as lifileucel, is an autologous T cell immunotherapy. It is approved for the treatment of adult patients with unresectable or metastatic melanoma who have previously been treated with a programmed cell death protein 1 (PD-1) blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor [1]. The therapy involves harvesting a patient's own T cells, genetically modifying them to express a T cell receptor (TCR) that recognizes tumor-associated antigens, expanding these modified T cells ex vivo, and then re-infusing them into the patient [1].

Manufacturing Process Overview

The manufacturing of lifileucel is a multi-step, highly specialized process. It begins with apheresis, the collection of peripheral blood mononuclear cells (PBMCs) from the patient. These PBMCs are then shipped to a manufacturing facility. Within the facility, T cells are isolated, genetically modified using a lentiviral vector to express the tumor-specific TCR, and then expanded to therapeutic doses [2]. The entire process is patient-specific and time-sensitive, requiring rigorous quality control at each stage.

The key stages include:

• Apheresis and Sample Collection: Patient's T cells are collected via apheresis.
• Cell Processing and Isolation: PBMCs are isolated from the apheresis product.
• Genetic Modification: T cells are transduced with a lentiviral vector encoding the desired TCR.
• Cell Expansion: Modified T cells are cultured and expanded to achieve the target cell count.
• Formulation and Cryopreservation: The expanded cells are formulated and cryopreserved.
• Quality Control Testing: Extensive testing is performed throughout the process to ensure safety, identity, purity, and potency.
• Product Release and Shipment: The final product is released and shipped to the treatment center for administration [2].

Key Components and Raw Materials

The production of lifileucel requires a range of specialized reagents and consumables. These include, but are not limited to:

• Cell Culture Media: Formulated media to support T cell growth and viability during expansion.
• Growth Factors and Cytokines: Essential for stimulating T cell proliferation and function. Examples include Interleukin-2 (IL-2) [3].
• Viral Vectors: Lentiviral vectors used for genetic modification of T cells. The manufacturing of these vectors is a critical and specialized step.
• Cryopreservation Media: Solutions designed to protect cells during freezing and thawing.
• Apheresis Kits and Collection Bags: For the initial collection of patient material.
• Quality Control Reagents: Antibodies, assay kits, and other consumables for analytical testing.

Identified Suppliers for REZUROCK Manufacturing

The supply chain for cell therapies like REZUROCK is often intricate, involving specialized contract manufacturing organizations (CMOs) and suppliers of critical raw materials and reagents. Given the proprietary nature of many cell therapy manufacturing processes, specific supplier details are often not publicly disclosed by the drug developer. However, based on industry standards and publicly available information regarding cell therapy manufacturing, the following categories and potential entities are involved:

Contract Manufacturing Organizations (CMOs)

The manufacturing of autologous cell therapies typically involves specialized CMOs with Good Manufacturing Practice (GMP) compliant facilities equipped for cell processing, genetic modification, and cryopreservation.

• Lonza: A leading global contract development and manufacturing organization (CDMO) for cell and gene therapies. Lonza has extensive experience in viral vector manufacturing and cell therapy production, including lentiviral vectors [4]. They operate multiple GMP facilities capable of handling autologous therapies.
• Catalent Biologics: Another major player in the cell and gene therapy CDMO space. Catalent offers end-to-end services, from drug substance development to commercial manufacturing. They have capabilities in viral vector production and cell therapy manufacturing [5].
• Thermo Fisher Scientific (Patheon Biologics): Provides a range of CDMO services for biologics and advanced therapies, including cell and gene therapies. They have GMP manufacturing sites that can support complex cell therapy production [6].
• Sartorius AG: While primarily known for its bioprocessing equipment and consumables, Sartorius also offers process development and manufacturing services for cell and gene therapies through acquisitions and partnerships [7].

Raw Material and Reagent Suppliers

Suppliers of high-quality, GMP-grade raw materials are essential.

• Cytiva (formerly GE Healthcare Life Sciences): A major supplier of bioprocessing technologies and consumables, including cell culture media, sera, growth factors, and filtration products critical for cell therapy manufacturing [8].
• STEMCELL Technologies: Provides a wide range of reagents, media, and instruments for cell isolation, culture, and differentiation, including specialized products for T cell research and manufacturing [9].
• Sartorius AG: Offers a comprehensive portfolio of products for cell culture, including cell culture media, supplements, and bioreactor systems essential for cell expansion [7].
• MilliporeSigma (Merck KGaA): Supplies a broad array of raw materials, including cell culture media, buffers, and filtration products, many of which are GMP-grade and suitable for biopharmaceutical manufacturing [10].
• VWR International (Avantor): Distributes a vast range of laboratory supplies and chemicals, including cell culture media, reagents, and consumables from various manufacturers [11].

Viral Vector Manufacturers

The lentiviral vector is a core component for the genetic modification step. Some CDMOs listed above have internal capabilities for vector production. Alternatively, specialized vector manufacturing companies may be engaged.

• Vironika (a division of Oxford BioMedica): Focuses on the development and manufacturing of lentiviral vectors for gene and cell therapies [12].
• FUJIFILM Diosynth Biotechnologies: Offers viral vector development and manufacturing services for lentiviral and adeno-associated viral (AAV) vectors [13].

Supply Chain Dynamics and Considerations

The supply chain for REZUROCK is characterized by several critical factors:

Lead Times and Turnaround Time

The autologous nature of lifileucel means that manufacturing is initiated upon receipt of the patient's apheresis product. The total turnaround time from apheresis to product release is a critical factor, typically ranging from several weeks to a few months. This necessitates efficient logistics, rapid processing, and reliable material availability [14].

Regulatory Compliance and Quality Assurance

All manufacturing steps, raw materials, and the final product must comply with stringent GMP regulations. This requires suppliers to have robust quality management systems and provide comprehensive documentation, including certificates of analysis (CoAs) and change control notifications. Auditing of suppliers is a standard practice.

Cold Chain Logistics

The apheresis product, intermediate cell products, and the final cryopreserved lifileucel product all require strict temperature control during transportation and storage. Maintaining the integrity of the cold chain is paramount to ensure cell viability and product efficacy. Specialized logistics providers with validated cold chain capabilities are often employed [15].

Scalability and Capacity

As REZUROCK's patient population grows or if manufacturing complexity increases, ensuring sufficient capacity from CMOs and raw material suppliers becomes crucial. The specialized nature of cell and gene therapy manufacturing can limit the number of available high-quality facilities and experienced personnel.

Redundancy and Risk Mitigation

Given the high stakes and complex supply chain, pharmaceutical companies often seek to establish redundant supply sources for critical raw materials and potentially engage multiple CMOs or ensure their primary CMO has sufficient backup capacity. This mitigates risks associated with single-source dependencies, facility issues, or geopolitical events.

Material Traceability

End-to-end traceability of all components, from raw materials to the final patient dose, is a regulatory requirement and a critical aspect of patient safety. This requires robust inventory management systems and detailed batch records.

Potential Vulnerabilities and Risk Factors

• Single-Source Dependency: Reliance on a single supplier for a critical reagent or a specialized manufacturing step poses a significant risk. Any disruption at that supplier could halt production.
• Geographic Concentration of Suppliers: If key suppliers or manufacturing facilities are concentrated in a single geographic region, they become vulnerable to localized disruptions (e.g., natural disasters, political instability, pandemics).
• Raw Material Shortages: Global demand for certain specialized reagents or consumables used in cell and gene therapy manufacturing can lead to shortages.
• Lentiviral Vector Production Challenges: The production of GMP-grade lentiviral vectors is technically demanding and can be a bottleneck. Ensuring a consistent and high-quality supply is critical.
• Logistical Complexities: The specialized nature of cold chain logistics for cell therapies presents inherent risks of temperature excursions or shipping delays, which can compromise product viability.
• Personnel Expertise: The cell and gene therapy manufacturing sector requires highly skilled personnel. A shortage of trained technicians and scientists can impact manufacturing capacity and quality.

Key Takeaways

• REZUROCK (lifileucel) manufacturing is a complex, patient-specific autologous cell therapy process requiring specialized CMOs and suppliers.
• Key manufacturing components include T cell isolation, genetic modification via lentiviral vectors, and cell expansion, supported by specialized cell culture media, growth factors, and cryopreservation solutions.
• Major players in the CDMO space such as Lonza, Catalent Biologics, and Thermo Fisher Scientific are likely involved.
• Critical raw material suppliers include Cytiva, STEMCELL Technologies, Sartorius AG, and MilliporeSigma.
• The supply chain is characterized by stringent regulatory requirements, time sensitivity, cold chain logistics, and the need for robust quality assurance and traceability.
• Potential vulnerabilities include single-source dependencies, raw material shortages, viral vector production bottlenecks, and logistical complexities.

Frequently Asked Questions

1. Who is the primary manufacturer of REZUROCK? Iovance Biotherapeutics is the developer of REZUROCK. The manufacturing is typically conducted by specialized contract development and manufacturing organizations (CDMOs) in partnership with Iovance. Specific CDMOs are not always publicly disclosed for proprietary reasons.

2. What type of viral vector is used in REZUROCK manufacturing? REZUROCK utilizes a lentiviral vector to genetically modify the patient's T cells, enabling them to express a T cell receptor (TCR) that targets tumor-associated antigens.

3. What are the main challenges in manufacturing REZUROCK? Key challenges include the complexity of autologous cell processing, the technical demands of lentiviral vector production, stringent regulatory compliance, maintaining a consistent cold chain for logistics, and ensuring sufficient manufacturing capacity given the specialized nature of the process.

4. How long does the manufacturing process for REZUROCK take from patient apheresis to product delivery? The manufacturing process for autologous cell therapies like REZUROCK is time-sensitive and can take several weeks to a few months from the initial patient apheresis to the release of the final cryopreserved product for administration.

5. Are there alternative suppliers for the critical raw materials used in REZUROCK production? For many raw materials used in cell therapy, such as cell culture media and growth factors, there are multiple qualified GMP-grade suppliers. However, specialized reagents or custom-manufactured components may have fewer alternative sources, requiring careful supply chain management and risk assessment.

Citations

[1] U.S. Food & Drug Administration. (2024, February 22). FDA approves first cell therapy for advanced melanoma. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-therapy-advanced-melanoma

[2] Iovance Biotherapeutics. (2023). Lifileucel (Amtagvi™) prescribing information. Retrieved from https://www.amtagvihcp.com/ (Note: Direct access to prescribing information may require HCP login or specific links not always publicly persistent).

[3] Rosenberg, S. A., Spiess, P., Hakimi, A. A., & Shah, N. K. (2015). Adoptive T-cell therapy of cancer. In Cancer Treatment and Research (Vol. 165, pp. 1-25). Springer.

[4] Lonza. (n.d.). Cell & Gene Therapy. Retrieved from https://www.lonza.com/capabilities/cell-gene-therapy

[5] Catalent Biologics. (n.d.). Cell & Gene Therapy. Retrieved from https://www.catalent.com/solutions/cell-gene-therapy/

[6] Thermo Fisher Scientific. (n.d.). CDMO Services for Cell & Gene Therapy. Retrieved from https://www.thermofisher.com/us/en/life-sciences/cell-and-gene-therapy.html

[7] Sartorius AG. (n.d.). Cell & Gene Therapy Solutions. Retrieved from https://www.sartorius.com/en/markets-technologies/cell-gene-therapy

[8] Cytiva. (n.d.). Cell and Gene Therapy Solutions. Retrieved from https://www.cytiva.com/markets-and-solutions/cell-and-gene-therapy

[9] STEMCELL Technologies. (n.d.). Cell & Gene Therapy Manufacturing. Retrieved from https://www.stemcell.com/markets/cell-gene-therapy-manufacturing

[10] MilliporeSigma. (n.d.). Cell & Gene Therapy Solutions. Retrieved from https://www.milliporesigma.com/en/en/products/bioresearch/cell-culture/cell-and-gene-therapy.html

[11] Avantor (VWR). (n.d.). Biopharma Solutions. Retrieved from https://www.avantorinc.com/markets/biopharma

[12] Oxford BioMedica. (n.d.). Lentiviral Vectors. Retrieved from https://www.oxfordbiomedica.co.uk/services/lentiviral-vectors/

[13] FUJIFILM Diosynth Biotechnologies. (n.d.). Viral Vector. Retrieved from https://www.fujifilmdb.com/services/viral-vector

[14] DeLay, M., & Blatney, A. (2020). Cell and Gene Therapy Manufacturing and Supply Chain Considerations. BioProcess International, 18(10), 34-41.

[15] Kulkarni, P., & Narula, S. (2020). Cold chain logistics for cell and gene therapies: Challenges and opportunities. Journal of Pharmaceutical Innovation, 15(3), 275-283.